Intellia Therapeutics (NTLA) Receivables - Net (2016 - 2025)
Intellia Therapeutics (NTLA) has disclosed Receivables - Net for 11 consecutive years, with $9.5 million as the latest value for Q4 2025.
- Quarterly Receivables - Net rose 11.54% to $9.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.5 million through Dec 2025, up 11.54% year-over-year, with the annual reading at $9.5 million for FY2025, 11.54% up from the prior year.
- Receivables - Net for Q4 2025 was $9.5 million at Intellia Therapeutics, up from $1.0 million in the prior quarter.
- The five-year high for Receivables - Net was $36.5 million in Q4 2023, with the low at $600000.0 in Q2 2024.
- Average Receivables - Net over 5 years is $8.2 million, with a median of $4.9 million recorded in 2023.
- The sharpest move saw Receivables - Net tumbled 88.13% in 2024, then skyrocketed 1600.0% in 2025.
- Over 5 years, Receivables - Net stood at $2.0 million in 2021, then surged by 85.52% to $3.8 million in 2022, then soared by 867.52% to $36.5 million in 2023, then plummeted by 76.64% to $8.5 million in 2024, then increased by 11.54% to $9.5 million in 2025.
- According to Business Quant data, Receivables - Net over the past three periods came in at $9.5 million, $1.0 million, and $10.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.